Generation Bio
GBIO
GBIO was delisted on the 6th of February, 2026.
81 hedge funds and large institutions have $1.2B invested in Generation Bio in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 32 increasing their positions, 25 reducing their positions, and 24 closing their positions.
28% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 25
2.42% more ownership
Funds ownership: 82.09% → 84.51% (+2.4%)
4% less capital invested
Capital invested by funds: $1.25B → $1.2B (-$46.5M)
17% less funds holding
Funds holding: 98 → 81 (-17)
67% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 24
93% less call options, than puts
Call options by funds: $216K | Put options by funds: $2.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$30.3M |
| 2 |
MWNA
Marshall Wace North America
New York
|
+$9.54M |
| 3 |
JP Morgan Chase
New York
|
+$8.23M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.8M |
| 5 |
BlackRock
New York
|
+$6.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$10.3M |
| 2 |
CC
Casdin Capital
New York
|
-$6.87M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$6.63M |
| 4 |
AIC
AWM Investment Company
New York
|
-$6.07M |
| 5 |
D.E. Shaw & Co
New York
|
-$2.8M |
GBIO Hedge Fund Activity: Q3 2021 in Review
81 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q3 2021, worth a combined $1.2B — down 3.7% from $1.25B a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of GBIO and 8 opened new positions — a net loss of 16 holders — while 25 trimmed existing stakes and 32 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $30.3M. The largest seller was State Street, cutting an estimated $10.3M.
- 81 institutional investors held Generation Bio (GBIO) as of Q3 2021, down from 98 in Q2 2021.
- Funds reported $1.2B of Generation Bio stock for Q3 2021, down 3.7% quarter-over-quarter.
- 8 funds opened new Generation Bio positions in Q3 2021 and 24 closed out, a net change of -16 holders.
- The largest Generation Bio buyer in Q3 2021 was T. Rowe Price Associates, an estimated $30.3M added.
- The largest Generation Bio seller in Q3 2021 was State Street, an estimated $10.3M sold.
Based on aggregated 13F filings for Q3 2021.